Annual report [Section 13 and 15(d), not S-K Item 405]

Document and Entity Information

v3.26.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 25, 2026
Jun. 30, 2025
Cover [Abstract]        
Entity Registrant Name Emmaus Life Sciences, Inc.      
Entity Central Index Key 0000822370      
Document Type 10-K      
Document Period End Date Dec. 31, 2025      
Amendment Flag false      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2025      
Current Fiscal Year End Date --12-31      
Entity File Number 001-35527      
Entity Tax Identification Number 87-0419387      
Entity Incorporation State Country Code DE      
Entity a Well-known Seasoned Issuer No      
Entity a Voluntary Filer No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Entity Shell Company false      
Entity Address, Address Line One 21250 Hawthorne Boulevard      
Entity Address, Address Line Two Suite 800      
Entity Address, City or Town Torrance      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 90503      
City Area Code 310      
Local Phone Number 214‑0065      
Document Annual Report true      
Document Transition Report false      
Entity Common Stock, Shares Outstanding     70,188,263  
Entity Public Float       $ 581,655
Title of 12(g) Security Common stock, par value $0.001 per share      
Auditor Name CBIZ CPAs P.C. Marcum llp    
Auditor Location Costa Mesa, California Costa Mesa, CA    
Auditor Firm ID 199 688    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Emmaus Life Sciences, Inc. (the “Company”) as of December 31, 2025, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ deficit and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Emmaus Life Sciences, Inc. (the “Company”) as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ deficit and cash flows for the year in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for year in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.